Bristol-Myers Squibb Co Valuation – April 2019 #BMY
Company Profile (excerpt from Reuters): Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Downloadable PDF version of this valuation:
ModernGraham Valuation of BMY – April 2019
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
| Defensive Investor; must pass 6 out of the following 7 tests. | ||||
| 1. Adequate Size of the Enterprise | Market Cap > $2Bil | $76,654,092,495 | Pass | |
| 2. Sufficiently Strong Financial Condition | Current Ratio > 2 | 1.61 | Fail | |
| 3. Earnings Stability | Positive EPS for 10 years prior | Pass | ||
| 4. Dividend Record | Dividend Payments for 10 years prior | Pass | ||
| 5. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | 51.08% | Pass | |
| 6. Moderate PEmg Ratio | PEmg < 20 | 17.33 | Pass | |
| 7. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 5.44 | Fail | |
| Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor. | ||||
| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5 | 1.61 | Pass | |
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1 | 0.87 | Pass | |
| 3. Earnings Stability | Positive EPS for 5 years prior | Pass | ||
| 4. Dividend Record | Currently Pays Dividend | Pass | ||
| 5. Earnings Growth | EPSmg greater than 5 years ago | Pass | ||
Stage 2: Determination of Intrinsic Value
| EPSmg | $2.71 |
| MG Growth Estimate | 15.00% |
| MG Value | $104.21 |
| Opinion | Undervalued |
| MG Grade | B |
| MG Value based on 3% Growth | $39.25 |
| MG Value based on 0% Growth | $23.01 |
| Market Implied Growth Rate | 4.42% |
| Current Price | $46.91 |
| % of Intrinsic Value | 45.02% |
Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio. The Enterprising Investor has no initial concerns. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.
As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.24 in 2015 to an estimated $2.71 for 2019. This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.42% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.
At the time of valuation, further research into Bristol-Myers Squibb Co revealed the company was trading above its Graham Number of $28.16. The company pays a dividend of $1.61 per share, for a yield of 3.4%, putting it among the best dividend paying stocks today. Its PEmg (price over earnings per share – ModernGraham) was 17.33, which was below the industry average of 45.96, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-2.26.
Bristol-Myers Squibb Co performs fairly well in the ModernGraham grading system, scoring a B.
Stage 3: Information for Further Research
| Net Current Asset Value (NCAV) | -$2.26 |
| Graham Number | $28.16 |
| PEmg | 17.33 |
| Current Ratio | 1.61 |
| PB Ratio | 5.44 |
| Current Dividend | $1.61 |
| Dividend Yield | 3.43% |
| Number of Consecutive Years of Dividend Growth | 12 |
Useful Links:
| ModernGraham tagged articles | Morningstar |
| Google Finance | MSN Money |
| Yahoo Finance | Seeking Alpha |
| GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
| Balance Sheet Information | 12/1/2018 |
| Total Current Assets | $17,160,000,000 |
| Total Current Liabilities | $10,654,000,000 |
| Long-Term Debt | $5,646,000,000 |
| Total Assets | $34,986,000,000 |
| Intangible Assets | $7,629,000,000 |
| Total Liabilities | $20,859,000,000 |
| Shares Outstanding (Diluted Average) | 1,637,000,000 |
Earnings Per Share History
| EPS History | |
| Next Fiscal Year Estimate | $4.10 |
| Dec2018 | $3.01 |
| Dec2017 | $0.61 |
| Dec2016 | $2.65 |
| Dec2015 | $0.93 |
| Dec2014 | $1.20 |
| Dec2013 | $1.54 |
| Dec2012 | $1.16 |
| Dec2011 | $2.16 |
| Dec2010 | $1.79 |
| Dec2009 | $5.34 |
| Dec2008 | $2.62 |
| Dec2007 | $1.09 |
| Dec2006 | $0.81 |
| Dec2005 | $1.52 |
| Dec2004 | $1.21 |
| Dec2003 | $1.59 |
| Dec2002 | $1.06 |
| Dec2001 | $0.95 |
| Dec2000 | $1.84 |
| Dec1999 | $1.81 |
Earnings Per Share – ModernGraham History
| EPSmg History | |
| Next Fiscal Year Estimate | $2.71 |
| Dec2018 | $1.90 |
| Dec2017 | $1.36 |
| Dec2016 | $1.65 |
| Dec2015 | $1.24 |
| Dec2014 | $1.45 |
| Dec2013 | $1.85 |
| Dec2012 | $2.21 |
| Dec2011 | $2.69 |
| Dec2010 | $2.74 |
| Dec2009 | $2.91 |
| Dec2008 | $1.61 |
| Dec2007 | $1.15 |
| Dec2006 | $1.20 |
| Dec2005 | $1.35 |
| Dec2004 | $1.29 |
| Dec2003 | $1.37 |
Recommended Reading:
Other ModernGraham posts about the company
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.
